source
- Cavalry Biosciences seeks $75M Series B to advance eye and muscle disorder candidatesCavalry Biosciences, the first company emerging from the Jupiter Bioventures incubator, announced it is pursuing a $75 million Series B financing round. The capital is intended to move its first t…
- Takeda braces for $2.5 billion charge after losing Amitiza antitrust case, plans appealTakeda Pharmaceutical has revised its financial outlook to include a potential $2.5 billion charge stemming from a recent antitrust lawsuit loss involving its laxative product Amitiza. The US Dist…